RFK Jr. Expands CDC Vaccine Advisory Panel's Scope Amid Legal Battles 
U.S. Sanctions Tanzanian Police Official Over Human Rights Violations 
Chicago U.S. Attorney Drops Charges Against Broadview Protest Defendants 
Why the future of marijuana legalization remains hazy despite high public support 
Sheinbaum Warns Morena Officials to Resign Over Corruption Allegations Amid U.S. Pressure 
CDC Monitors 41 Americans After Andes Hantavirus Outbreak on Luxury Cruise Ship 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Raul Castro Indicted by U.S.: Cuba’s Revolutionary Leader Faces Renewed Scrutiny in 2026 
Trump Delays Iran Strike as Peace Talks Continue, Markets Watch Strait of Hormuz Closely 
Rubio Pressures NATO Allies as Trump Questions Alliance Commitment 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
The four types of dementia most people don’t know exist 
Trump Signals Tough Stance on Iran Uranium Stockpile as Nuclear Talks Show Limited Progress 
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) is facing leadership uncertainty after acting director Jeffery Taubenberger stepped down during ongoing Ebola and hantavirus outbreak concerns. The departure was revealed Thursday during a Senate hearing on the National Institutes of Health (NIH) 2027 budget, sparking criticism from Democratic lawmakers over the agency’s preparedness for emerging infectious diseases.
Taubenberger assumed the acting director role in April 2025 after the Trump administration removed former NIAID leadership. Senator Tammy Baldwin announced his resignation at the hearing, while Senator Patty Murray also referenced the sudden exit. NIH Director Jay Bhattacharya did not deny the reports and said the agency is shifting priorities away from civilian biodefense and pandemic preparedness toward direct infectious disease response, allergy research, and immunology.
The leadership change comes as global health officials monitor an Ebola outbreak in the Democratic Republic of Congo and potential hantavirus exposure linked to a luxury cruise ship outbreak in the Atlantic Ocean. Although no confirmed U.S. cases of Andes hantavirus have been reported, 41 individuals, including 18 people quarantined in Nebraska, remain under observation.
Former NIAID director Jeanne Marrazzo criticized the current situation, warning that the institute appears disconnected from researchers and pharmaceutical companies working on Ebola treatments. Under former director Anthony Fauci, NIAID played a major role in managing both the COVID-19 pandemic and the 2014-2016 Ebola crisis in West Africa.
The latest departures add to growing concerns about instability within the NIH, where more than half of its 27 institutes are currently overseen by acting directors. NIAID, the NIH’s second-largest institute with a budget exceeding $6.5 billion, remains central to U.S. infectious disease research and public health response efforts.
